Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

NVS vs GILD: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

GILD Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 4–6 Matrix Metrics)

GILD Overall Winner 6-Pillar Tally: NVS 1 – 5 GILD Matrix Metrics: NVS 6 – 4 GILD

As of Nov 16, 2026, Gilead Sciences Inc (GILD) is the stronger overall head-to-head candidate over Novartis AG (NVS) in the Tradestie Institutional Equity Comparison Engine, winning 4–6 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). NVS carries a Unified Composite Score of 41.5/100 (SELL) at $161.59 (16.2x Forward P/E, 34.0% operating margin), whereas GILD carries 40.1/100 (SELL) at $169.09 (16.6x Forward P/E, 38.2% operating margin).

  • Composite vs. Pillar Nuance: While NVS currently prints a higher short-term Unified Composite Score (41.5/100 SELL vs. GILD 40.1/100 SELL), GILD captures the overall institutional head-to-head verdict (4–6 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (38.2% vs. 34.0% operating margin) and revenue trajectory (+6.8% vs. +4.7% YoY).
  • Defensive Composite Rating Caution: Although GILD compares more favorably head-to-head, both NVS (41.5/100 SELL) and GILD (40.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About NVS vs GILD
NVS NYSE
Novartis AG
Pharmaceutical Preparations
$161.59
+0.68% 1D
Market Cap $302.9B
TTM Revenue $40.5B
Forward P/E 16.2x
Beta / 30D Vol 0.31β · 27% Vol
Unified Composite Score
41.5 / 100 SELL
Tech 29.0 Fund 38.0 Flow 50.0 Mom 21.1
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (0.7% over 20 days), RSI 61
RSI-14: 60.8 · SMA20: $159.19 · SMA50: $149.17
GILD NASDAQ Head-to-Head Winner
Gilead Sciences Inc
Biological Products, (No Disgnostic Substances)
$169.09
+0.6% 1D
Market Cap $208.3B
TTM Revenue $31.0B
Forward P/E 16.6x
Beta / 30D Vol 0.34β · 32% Vol
Unified Composite Score
40.1 / 100 SELL
Tech 24.0 Fund 47.0 Flow 70.0 Mom 46.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (5.6% over 20 days), RSI 62
RSI-14: 61.6 · SMA20: $164.95 · SMA50: $155.48

6-Pillar Scorecard Institutional Category Breakdown (NVS 1 – 5 GILD)

Columns: Metric · NVS · GILD
1. Valuation Multiples GILD
Forward P/E 16.2x 16.6x
Trailing P/E 30.6x 17.0x
PEG Ratio 3.81x 2.29x
EV / Revenue 7.5x 7.4x
2. Growth & Scale GILD
Revenue Growth (YoY) +4.7% +6.8%
Earnings Growth (YoY) -68.8% -20.2%
TTM Revenue (USD) $40.5B $31.0B
Market Cap $302.9B $208.3B
3. Profitability & Quality GILD
Gross Margin 75.2% 79.9%
Operating Margin 34.0% 38.2%
Net Profit Margin 17.5% -12.5%
Return on Equity (ROE) 24.3% -22.4%
4. Balance Sheet & Cash Flow NVS
Cash Generation (TTM) $17.0B EBITDA $13.8B
Cash Flow Margin 42.0% EBITDA Mgn 44.5%
Net Cash / Leverage $19.71 Book/Sh · 24.3% ROE $19.8B Net Debt (2.01x D/E)
Dividend Yield 2.96% 1.91%
5. Options & Positioning GILD
Options Structure Phase UNCLASSIFIED SURGE
Current IV / %ile 16.9% (6th %ile) 29.3% (10th %ile)
Put/Call OI Skew Thin ADR Chain 0.63x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markup DISTRIBUTION · Markup
6. R&D & Supply-Chain Moat GILD
OpEx & R&D Intensity 41.2% of Rev ($16.7B) 41.7% of Rev ($12.9B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat High-Margin Pricing Power Moat
Supply-Chain Role Drug Manufacturers - General Operator Drug Manufacturers - General Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: NVS (6) vs GILD (4)
Institutional Metric NVS GILD Criterion Row Edge
Market Capitalization
Scale
$302.9B $208.3B Larger Scale NVS
Trailing P/E Ratio
Valuation
30.6x 17.0x Lower Multiple GILD
Forward P/E Ratio
Valuation
16.2x 16.6x Lower Multiple NVS
Revenue Growth (YoY)
Growth
+4.7% +6.8% Higher Growth GILD
Operating Margin (TTM)
Profitability
34.0% 38.2% Higher Margin GILD
Net Profit Margin
Profitability
17.5% -12.5% Higher Margin NVS
Return on Equity (ROE)
Capital Efficiency
24.3% -22.4% Higher ROE NVS
52-Week Range Position
Momentum
81% ($123–$170) 88% ($117–$177) Stronger Trend GILD
Beta / 30D Volatility
Risk Regime
0.31β · 27% Vol 0.34β · 32% Vol Lower Realized Risk NVS
Unified Institutional Score
Composite Signal
41.5 / 100 (SELL) 40.1 / 100 (SELL) Higher Composite NVS
Trailing 12M Revenue (USD)
Operating Scale
$40.5B $31.0B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
75.2% 79.9% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
3.81x PEG · 7.5x EV/Rev 2.29x PEG · 7.4x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$17.0B EBITDA ($19.71 Book/Sh · 24.3% ROE) $13.8B ($19.8B Net Debt (2.01x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon GILD +0.98 pp
NVS: +7.28% · GILD: +8.26%
3M Horizon GILD +13.33 pp
NVS: +4.56% · GILD: +17.89%
6M Horizon GILD +22.06 pp
NVS: +8.34% · GILD: +30.4%
1Y Horizon GILD +12.56 pp
NVS: +22.5% · GILD: +35.06%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on NVS vs GILD. Trailing 12-month operating profitability (NVS 34.0% vs GILD 38.2%) and valuation multiples (NVS 16.2x vs GILD 16.6x Forward P/E) are benchmarked directly in Pillar 4 below.

NVS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$40.5B
Gross Margin75.2%
Op. Margin34.0%
ROE / Fwd P/E24.3% · 16.2x
GILD ADR TTM Benchmark FX-Normalized USD
TTM Revenue$31.0B
Gross Margin79.9%
Op. Margin38.2%
ROE / Fwd P/E-22.4% · 16.6x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
NVS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 16.9%
IV Percentile 6th %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact NVS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
GILD SURGE
7d in phase · OBV DISTRIBUTION
Current IV 29.3%
IV Percentile 10th %ile
Put/Call OI Skew 0.63x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact GILD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
NVS Moat Profile High-Margin Pricing Power Moat
Drug Manufacturers - General Operator
Competes within the Drug Manufacturers - General value chain with $302.9B market capitalization and 34.0% operating margin.
OpEx & R&D Reinvestment 41.2% of Rev ($16.7B)
90D Engineering Disclosures 0 Published
GILD Moat Profile High-Margin Pricing Power Moat
Drug Manufacturers - General Operator
Competes within the Drug Manufacturers - General value chain with $208.3B market capitalization and 38.2% operating margin.
OpEx & R&D Reinvestment 41.7% of Rev ($12.9B)
90D Engineering Disclosures 0 Published

Investor FAQ NVS vs GILD Key Questions & Quantitative Answers

As of Nov 16, 2026, Gilead Sciences Inc (GILD) is the stronger overall head-to-head candidate over Novartis AG (NVS) in the Tradestie Institutional Equity Comparison Engine, winning 4–6 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). NVS carries a Unified Composite Score of 41.5/100 (SELL) at $161.59 (16.2x Forward P/E, 34.0% operating margin), whereas GILD carries 40.1/100 (SELL) at $169.09 (16.6x Forward P/E, 38.2% operating margin). Composite vs. Pillar Nuance: While NVS currently prints a higher short-term Unified Composite Score (41.5/100 SELL vs. GILD 40.1/100 SELL), GILD captures the overall institutional head-to-head verdict (4–6 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (38.2% vs. 34.0% operating margin) and revenue trajectory (+6.8% vs. +4.7% YoY). Defensive Composite Rating Caution: Although GILD compares more favorably head-to-head, both NVS (41.5/100 SELL) and GILD (40.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

GILD leads the Growth & Scale pillar: NVS posts +4.7% YoY revenue growth and -68.8% YoY earnings growth on $40.5B TTM revenue (75.2% gross margin, 34.0% operating margin), compared with GILD at +6.8% YoY revenue growth and -20.2% YoY earnings growth on $31.0B TTM revenue (79.9% gross margin, 38.2% operating margin). On trailing 12-month operating scale, NVS generates $40.5B in USD-normalized revenue versus $31.0B for GILD. In operating R&D and SG&A reinvestment, NVS deploys 41.2% of Rev ($16.7B) (0 90-day corporate R&D disclosures) versus 41.7% of Rev ($12.9B) (0 disclosures) for GILD.

GILD screens cheaper on headline valuation multiples. NVS trades at 16.2x Forward P/E, 30.6x Trailing P/E, 3.81x PEG, and 7.5x EV/Revenue (42.0% EBITDA margin), whereas GILD trades at 16.6x Forward P/E, 17.0x Trailing P/E, 2.29x PEG, and 7.4x EV/Revenue (44.5% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NVS (24.3% ROE) versus GILD (-22.4% ROE) capital efficiency.

In options market volatility and institutional positioning, NVS carries 16.9% implied volatility (6th %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.31β · 27% Vol realized risk). By comparison, GILD carries 29.3% implied volatility (10th %ile, Compressed (<25th %ile)), a 0.63x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a SURGE options structure phase (0.34β · 32% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.